Search results
Results From The WOW.Com Content Network
Paroxetine, sold under the brand name Paxil among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class [7] used to treat major depressive disorder, obsessive–compulsive disorder (OCD), panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder, and premenstrual dysphoric disorder. [7]
If you have bothersome ED or other side effects from an antidepressant, don’t abruptly stop taking it. Abruptly stopping your medication can result in flu-like symptoms, such as nausea, headache ...
Paroxetine (Paxil, Pexeva) ... You can take escitalopram after eating a meal or on an empty stomach. ... Never stop taking the medication or adjust your dosage without speaking to your healthcare ...
Online, people claim they get brain zaps after stopping use of drugs like Lexapro (escitalopram), Cymbalta (duloxetine), and Paxil (paroxetine), but they can happen when you stop taking any type ...
Post-SSRI sexual dysfunction (PSSD) [63] [64] refers to a set of symptoms reported by some people who have taken SSRIs or other serotonin reuptake-inhibiting (SRI) drugs, in which sexual dysfunction symptoms persist for at least three months [65] [66] [67] after ceasing to take the drug. The status of PSSD as a legitimate and distinct pathology ...
To find the most effective pharmaceutical drug treatment, the dosages of medications must often be adjusted, different combinations of antidepressants tried, or antidepressants changed. [citation needed] Some of the medications have side effects that affect certain people in different ways. The combinations of medication can change these side ...
You may need to use this technique if you’re using an antidepressant that can interact with the other medication. Taper and conservative switch with a medication-free washout period.
Over two million prescriptions for paroxetine were written for children or adolescents in the US in 2002. [29]Funded by SmithKline Beecham, the acute phase of study 329 was an eight-week, double-blind, randomized clinical trial conducted in 12 university or hospital psychiatric departments in the United States and Canada between 1994 and 1997.